Last reviewed · How we verify
The Effect of Cerebrolysin on the Blood-brain-barrier in Patients With Diabetes and Ischemic Stroke
A prospective, single-center study would be carried out in the Neurology Department of the University Hospital "Dr. José Eleuterio González" in order to analyze the effect of cerebrolysin on the blood-brain-barrier in patients with ischemic stroke with personal history of type-2 diabetes
Details
| Lead sponsor | Hospital Universitario Dr. Jose E. Gonzalez |
|---|---|
| Phase | Phase 4 |
| Status | UNKNOWN |
| Enrolment | 60 |
| Start date | 2022-11-17 |
| Completion | 2024-12 |
Conditions
- Ischemic Stroke, Acute
- Diabetes Mellitus, Type 2
- Blood Brain Barrier
Interventions
- Cerebrolysin
- Brain-MRI with contrast after 10-14 days of cerebrolysin
Primary outcomes
- Blood-Brain-Barrier Permeability after 10-14days of cerebrolysin in patients with AIS of the middle cerebral artery — After 10-14 days of cerebrolysin
Blood-brain barrier (BBB) disruption will be measured using dynamic susceptibility contrast (DSC) magnetic resonance imaging (MRI).DSC MRI is collected during the injection of a gadolinium bolus and the majority of the change in recorded signal in this T2\*-weighted sequence is due to intravascular contrast. However, in the setting of gadolinium leakage through the BBB into the brain parenchyma, the recorded signal is altered by a T1 effect. An arrival time correction is performed to account for regional difference in blood flow after which the signal is separated into an intravascular and an extravascular component using a comparison with unaffected tissue. The extravascular component is captured with the metric K2 which reflects the fraction of the recorded signal that is due to gadolinium leakage and is a measure of BBB disruption.
Countries
Mexico